Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

FDA approves Zeposia® (ozanimod) to treat relapsing forms of multiple sclerosis

10
SHARES

The US FDA has granted approval to BMS for Zeposia, a once daily oral medication for the treatment of relapsing forms of multiple sclerosis.

Stem cell transplants may slow disability progression in MS

The US Food and Drug Administration (FDA) has given its approval to Zeposia® (ozanimod) for the treatment of relapsing forms of multiple sclerosis (RMS). 

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Produced by Bristol-Myers Squibb (BMS), Zeposia 0.92mg is an oral medication taken once daily and is the only approved sphingosine-1-phosphate (S1P) receptor modulator that offers RMS patients an initiation with no genetic test and no label-based first-dose observation. 

The drug is a S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5. It blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which ozanimod exerts therapeutic effects in multiple sclerosis is unknown but may involve the reduction of lymphocyte migration into the central nervous system (CNS).

“With the FDA approval of Zeposia, appropriate patients with RMS will have another oral treatment option with meaningful efficacy to help address the disease’s hallmark relapses and brain lesions,” said Dr Samit Hirawat, Chief Medical Officer at BMS. “Zeposia has substantial clinical potential and we are well positioned with our heritage in transformational science to ensure this innovative compound ultimately benefits as many patients as possible.”

The approval is based on data from the randomised, active-controlled Phase III SUNBEAM™ (safety and efficacy of Zeposia versus interferon beta-1a in RMS) and RADIANCE™ (safety and efficacy of the selective sphingosine 1-phosphate receptor modulator Zeposia in RMS) clinical trials. In both trials, the drug demonstrated powerful efficacy, measured by annualised relapse rate (ARR), as well as on the number and size of brain lesions.

As the US healthcare system is dealing with the unprecedented COVID-19 pandemic, BMS has made the decision to delay commercialisation of Zeposia. 

A marketing authorisation application for Zeposia for the treatment of adults with relapsing-remitting multiple sclerosis in the EU is currently under review with the European Medicines Agency (EMA). A regulatory decision is expected in the first half of 2020.

Share via
Share via